Calcified Tissue Research

, Volume 3, Issue 1, pp 318–326 | Cite as

Osteogenesis imperfecta: Effect of magnesium administration on pyrophosphate metabolism

  • C. C. Solomons
  • J. Styner
Original Papers


The bone collagen of human osteogenesis imperfecta is a potent inhibitor ofin vitro calcification. The inhibition was removed by treatment of the collagen with pyrophosphate in the presence of magnesium ions. Elevated levels of serum and urinary inorganic pyrophosphate were found in 28 patients with osteogenesis imperfecta. Oral administration of magnesium oxide or magnesium sulfate to four of these patients significantly reduced their serum and urinary levels of pyrophosphate.

Key words

Osteogenesis Imperfecta Pyrophosphate Magnesium Pyrophosphatase 


Du collagène osseux provenant de fragments d'ostéogenèse imparfaite est un puissant inhibiteur de la calcificationin vitro. Cet effet inhibiteur peut être supprimé par traitement du collagène à la pyrophosphatase en présence d'ions de magnésium. Des concentrations élevées de pyrophosphates inorganiques sérique et urinaire ont été observées chez 28 malades atteints d'ostéogenèse imparfaite. L'administration buccale d'oxyde de magnésium ou de sulfate de magnésium à quatre de ces malades diminue de façon significative la quantité des pyrophosphates sérique et urinaire.


Der Knochenkollagen von Osteogenesis imperfecta-Kranken ist ein mächtiger Hemmstoff für die Verkalkung in vitro. Die Inhibition wird durch Behandlung des Kollagens mit Pyrophosphatase in Anwesenheit von Magnesiumionen aufgehoben. Erhöhte Spiegel von anorganischem Pyrophosphat wurden im Urin und im Serum von 28 Kranken mit Osteogenesis imperfecta gefunden. Wurden 4 Patienten mit peroralen Gaben von Magnesiumoxyd oder Magnesiumsulfat behandelt, so verminderte sich der Pyrophosphatspiegel im Serum und im Urin signifikant.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Avioli, L. V., J. E. McDonald, andR. A. Singer: Excretion of pyrophosphate in disorders of bone metabolism. J. clin. Endocr.25, 912–915 (1965).PubMedGoogle Scholar
  2. Bongiovani, A. M., M. M. Album, A. W. Root, andJ. W. Hope: Metabolic studies in hypophosphatasia and response to high phosphate intake. Abstr. Soc. Ped. Res. Pg. 6 (April 1967).Google Scholar
  3. Chen, P. S., T. Y. Toribara, andH. Warner: Microdetermination of phosphorus. Analyt. Chem.28, 1756–1758 (1956).Google Scholar
  4. Clark, I.: Effects of magnesium ions on calcium and phosphorus metabolism. Amer. J. Physiol.214, 348–356 (1968).PubMedGoogle Scholar
  5. Fleisch, H., andS. Bisaz: Mechanisms of calcification: Inhibitory role of pyrophosphate. Nature (Lond.)195, 911 (1962a).Google Scholar
  6. ——: Isolation from urine of pyrophosphate, a calcification inhibitor. Amer. J. Physiol.203, 671–675 (1962b).PubMedGoogle Scholar
  7. —, andW. F. Neuman: Mechanisms of calcification: Role of collagen, polyphosphates, and phosphatase. Amer. J. Physiol.200, 1296–1300 (1961).PubMedGoogle Scholar
  8. —, andR. G. G. Russell, andS. Bisaz: Influence of pyrophosphate on the transformation of amorphous to crystalline calcium phosphate. Calc. Tiss. Res.2, 49–59 (1968).Google Scholar
  9. Gitelman, H. J., S. Kukolj, andL. G. Welt: Inhibition of parathyroid gland activity by hypermagnesemia. Amer. J. Physiol.215, 483–485 (1968).PubMedGoogle Scholar
  10. Horn, A., H. Bornig, andG. Thiele: Allosteric properties of the magnesium-dependent inorganic pyrophosphatase in mouse liver cytoplasm. Europ. J. Biochem.2, 243–249 (1967).PubMedGoogle Scholar
  11. Irving, J. T., D. Schibler, andH. Fleisch: Bone formation in normal and Vit. D-treated rachitic rats during the administration of polyphosphates. Proc. Soc. exp. Biol. (N.Y.)122, 852–856 (1966).Google Scholar
  12. MacIntyre, I.: The flame spectrophotometric determination of calcium in biological fluids and on isotopic analysis of the errors in the Kramer-Tisdall Procedure. Biochem. J.67, 164–172 (1957).PubMedGoogle Scholar
  13. Neuman, W. F.: Metabolic interrelations.: Josiah Macy Jr. Foundation, 187 (1950); 205 (1951).Google Scholar
  14. —, andM. W. Neuman: The chemical dynamics of bone mineral., p. 31. Chicago: Chicago University Press 1958.Google Scholar
  15. Sauberlich, H. E., G. E. Bunce, C. A. Moore, andO. G. Stonington: Oral magnesium in the treatment of renal calculus formation. Amer. J. clin. Nutr.14, 240 (1964).Google Scholar
  16. Siegel, B. M., I. A. Friedman, andS. O. Schwartz: Hemorrhagic disease in osteogenesis imperfecta. Amer. J. Med.22, 315–321 (1957).PubMedGoogle Scholar
  17. Solomons, C. C.: The control of calcification in osteogenesis imperfecta. Society for Pediatric Research Abstr., p. 38 (1967).Google Scholar
  18. —, andW. F. Neuman: On the mechanisms of calcification: The remineralization of dentin. J. biol. Chem.235, 2502–2506 (1960).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1969

Authors and Affiliations

  • C. C. Solomons
    • 2
    • 1
  • J. Styner
    • 2
    • 1
  1. 1.Department of OrthopedicsUniversity of Colorado Medical SchoolDenver
  2. 2.Department of PediatricsUniversity of Colorado Medical CenterDenver

Personalised recommendations